
Vitor Trovisco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11189924/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Gene Ontology resource: enriching a GOld mine. Nucleic Acids Research, 2021, 49, D325-D334.	14.5	2,416
2	FlyBase 2.0: the next generation. Nucleic Acids Research, 2019, 47, D759-D765.	14.5	697
3	BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene, 2003, 22, 4578-4580.	5.9	616
4	FlyBase: updates to the <i>Drosophila melanogaster</i> knowledge base. Nucleic Acids Research, 2021, 49, D899-D907.	14.5	374
5	BRAF mutations are associated with some histological types of papillary thyroid carcinoma. Journal of Pathology, 2004, 202, 247-251.	4.5	334
6	Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 446, 589-595.	2.8	242
7	BRAFMutations Are Not a Major Event in Post-Chernobyl Childhood Thyroid Carcinomas. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4267-4271.	3.6	171
8	Analysis of the expression patterns, subcellular localisations and interaction partners of <i>Drosophila</i> proteins using a <i>pigP</i> protein trap library. Development (Cambridge), 2014, 141, 3994-4005.	2.5	160
9	BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 444, 572-6.	2.8	108
10	A new BRAF gene mutation detected in a case of a solid variant of papillary thyroid carcinoma. Human Pathology, 2005, 36, 694-697.	2.0	93
11	Intragenic Mutations in Thyroid Cancer. Endocrinology and Metabolism Clinics of North America, 2008, 37, 333-362.	3.2	87
12	Mutation analysis of B-RAF gene in human gliomas. Acta Neuropathologica, 2005, 109, 207-210.	7.7	85
13	Molecular and Genotypic Characterization of Human Thyroid Follicular Cell Carcinoma–Derived Cell Lines. Thyroid, 2007, 17, 707-715.	4.5	81
14	B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. Human Pathology, 2006, 37, 781-786.	2.0	72
15	Harmonizing model organism data in the Alliance of Genome Resources. Genetics, 2022, 220, .	2.9	52
16	Molecular genetics of papillary thyroid carcinoma: great expectations Arquivos Brasileiros De Endocrinologia E Metabologia, 2007, 51, 643-653.	1.3	28
17	Acquisition of <i>BRAF</i> gene mutations is not a requirement for nodal metastasis of papillary thyroid carcinoma. Clinical Endocrinology, 2008, 69, 683-685.	2.4	27
18	The p75 neurotrophin receptor is widely expressed in conventional papillary thyroid carcinoma. Human Pathology, 2006, 37, 562-568.	2.0	26

VITOR TROVISCO

#	Article	IF	CITATIONS
19	Oskar Is Targeted for Degradation by the Sequential Action of Par-1, GSK-3, and the SCF-Slimb Ubiquitin Ligase. Developmental Cell, 2013, 26, 303-314.	7.0	21
20	In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp. Endocrine-Related Cancer, 2011, 18, 401-412.	3.1	11
21	Reply to: Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Letters, 2005, 230, 149-150.	7.2	4
22	Germline variation of the melanocortinâ€l receptor does not explain shared risk for melanoma and thyroid cancer. Experimental Dermatology, 2009, 18, 548-552.	2.9	4